3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
8
Phase 1
6
Phase 3
4
Phase 1/2
3
Phase 2/3
1
Status
Completed
4
Sponsor Class
INDUSTRY
4
Study Type
Interventional
4
Sponsor
Cancer Type
Breast
3
Endocrine
2
Tumor-Agnostic
1
Conditions
Breast Neoplasms
65
Neoplasm Metastasis
11
Advanced Breast Cancer
5
Neoplasms
4
Recurrence
2
Multiple Endocrine Neoplasia Type 1
2
Locally Advanced (Inoperable) or Metastatic Breast Cancer
2
Hereditary Sensory and Autonomic Neuropathies
2
Unilateral Breast Neoplasms
1
Neoplasms by Site
1
HR-positive, HER2-negative Breast Neoplasms
1
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
1
Disease Progression
1
Carcinoma, Lobular
1
Carcinoma, Ductal, Breast
1
Breast Neoplasm Female
1
Breast Diseases
1
Interventions
Paclitaxel
20
Gemcitabine
16
Dexamethasone
16
Bevacizumab
16
Docetaxel
15
Oxaliplatin
14
Cyclophosphamide
13
Carboplatin
12
Capecitabine
12
Sorafenib
11
Fluorouracil
11
Leucovorin
10
Cisplatin
10
pembrolizumab
9
Pemetrexed
9
Epoetin Alfa
9
venetoclax
8
Prednisone
8
Fentanyl
8
Drug Therapy
8
Doxorubicin
8
atezolizumab
7
Rivaroxaban
7
Rituximab
7
Darbepoetin alfa
7
Anastrozole
7
Panitumumab
6
Ondansetron
6
Morphine
6
Irinotecan
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
Phase 3
×
Neoplasms
×
Fulvestrant
×
Clear all
NCT01602380
2026-02-27
FALCON
AstraZeneca
Phase 3
Completed
462 enrolled
20 charts
NCT02437318
2025-02-13
SOLAR-1
Novartis
Phase 3
Completed
572 enrolled
22 charts
1 FDA
NCT02422615
2023-11-30
MONALEESA-3
Novartis
Phase 3
Completed
726 enrolled
17 charts
1 FDA
NCT00256698
2012-08-01
FACT
AstraZeneca
Phase 3
Completed
514 enrolled
13 charts